At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
bevacizumab (Avastin) +1 moredrug
Likely dose
bevacizumab (Avastin) 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm, Open Label Study of First Line Treatment With Tarceva Plus Avastin on Progression-free Survival in Patients With Advanced or Metastatic Liver Cancer
In Brief
A Phase 2 clinical trial evaluating bevacizumab (Avastin) and erlotinib (Tarceva) for Liver Cancer. Completed, enrolled 51 participants across 6 sites in 3 countries.
Detailed Summary
This single arm study evaluated the efficacy and safety of a combination of Tarceva and Avastin in patients with advanced or metastatic liver cancer. Patients were treated with Tarceva 150 mg po daily plus Avastin 5 mg/kg intravenous (iv) every 2 weeks. The anticipated time on study treatment was until disease progression, and the target sample size was \<100 individuals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cancer
CountriesPhilippines, South Korea, Taiwan
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2008
Enrollment StartMar 2008
Primary CompletionSep 2010
TodayJul 2026
First PostedJan 31, 2008
Enrollment StartMar 1, 2008
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.4 years ago
Interventions
bevacizumab (Avastin)drug
5 mg/kg iv on day 1 of each 2 week cycle.
erlotinib (Tarceva)drug
150 mg orally (po) daily.